Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785)
- PMID: 29268871
- DOI: 10.1016/j.ophtha.2017.08.024
Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785)
Comment in
-
Reply.Ophthalmology. 2018 Jan;125(1):e11-e12. doi: 10.1016/j.ophtha.2017.08.023. Ophthalmology. 2018. PMID: 29268872 No abstract available.
Comment on
-
Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.Ophthalmology. 2017 Jun;124(6):776-785. doi: 10.1016/j.ophtha.2017.01.036. Epub 2017 Mar 6. Ophthalmology. 2017. PMID: 28268098 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources